NCT02598232

Brief Summary

This study aims to evaluate the efficacy and safety of the 1,414nm Nd:YAG laser system (ACCUPLASTI) added to Percutaneous Epidural Neuroplasty (PEN), a conventional treatment, to alleviate back pain in a lumbar herniated intervertebral disc patient.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Oct 2014

Shorter than P25 for phase_2

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2014

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2015

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

November 4, 2015

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 5, 2015

Completed
Last Updated

March 9, 2017

Status Verified

April 1, 2016

Enrollment Period

1 year

First QC Date

November 4, 2015

Last Update Submit

March 7, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in the Oswestry Disability Index

    Day 0, 24 weeks

Secondary Outcomes (4)

  • Change in the Oswestry Disability Index

    Day 0, 4 weeks, 12 weeks

  • Change in the Visual Analogue Scale

    Day 0, 4 weeks, 12 weeks, 24 weeks

  • 12-Item Short-form Health Survey

    Day 0, 4 weeks, 12 weeks, 24 weeks

  • Evaluation of the pain level in 4 steps of excellent, good, fair, poor, according to MacNab's Criteria

    Day 0, 4 weeks, 12 weeks, 24 weeks

Study Arms (1)

1,414nm Nd:YAG laser

EXPERIMENTAL

It has high absorption coefficient in water and a short pulse width.

Device: 1,414nm Nd:YAG Laser System

Interventions

It has high absorption coefficient in water and a short pulse width.

1,414nm Nd:YAG laser

Eligibility Criteria

Age19 Years - 79 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patients 19-79 years old
  • Patients with moderate disability based on the Oswestry Disability Index (ODI), among those diagnosed with a single level of unilateral herniated intervertebral disc among the 3rd-4th and 4th-5th lumbar vertebrae, or the 5th lumbar vertebra-sacral vertebra with back pain or radiating pain in the lower extremities that has been unresponsive to conservative therapy for more than six weeks
  • Patients who have language skills enough to answer questionnaires
  • Patients who agree to voluntarily participate in this study and to sign the Informed Consent Form, and who are able to participate for the entire period of this study

You may not qualify if:

  • Patients with a multi-level, far-lateral, or bilateral lumbar herniated intervertebral disc
  • Patients who use an electronic medical device for their cardiovascular system
  • Patients who have spondylolisthesis in the relevant lesion
  • Patients with neurological defects
  • Patients who had undergone surgery on the relevant lumbar vertebra
  • Patients with cauda equina syndrome
  • Patients with congenital spinal deformity
  • Patients with spinal fracture
  • Patients with spinal infection, tumor, or other form of inflammatory spondylopathy
  • Patients with coagulation disorder
  • Patients with a history of malignant tumor (except those with a cured tumor and no re- occurrence for the last five years)
  • Patients who had participated in another clinical study within 30 days from their screening visit
  • Female patients with child-bearing potential who do not agree to use a medically acceptable contraceptive method\* for up to 24 weeks after the use of the investigational medical device during this study
  • Medically acceptable contraceptive method: Condom, oral contraceptive pills taken continuously for more than three months, contraceptive injection or implants, intra- uterine contraceptive device, etc.
  • Patients who are pregnant or breastfeeding
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Intervertebral Disc Displacement

Condition Hierarchy (Ancestors)

Spinal DiseasesBone DiseasesMusculoskeletal DiseasesHerniaPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Study Officials

  • Keung-nyun Kim, Professor

    Severance Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 4, 2015

First Posted

November 5, 2015

Study Start

October 1, 2014

Primary Completion

October 1, 2015

Study Completion

October 1, 2015

Last Updated

March 9, 2017

Record last verified: 2016-04

Data Sharing

IPD Sharing
Will not share